MicroRNA-552 Promotes Hepatocellular Carcinoma Progression by Downregulating WIF1
Overview
Affiliations
MicroRNAs (miRNAs/miRs) are involved in the metastasis of hepatocellular carcinoma (HCC). In the present study, it was demonstrated that miR‑552 was upregulated in HCC tissues. High miR‑552 expression was associated with malignant clinicopathological features and decreased survival rates. The in vitro results indicated that miR‑552 overexpression promoted migration, invasion and epithelial‑mesenchymal transition in Hep3B cells. However, the knockdown of miR‑552 inhibited its oncogenic roles in Huh‑7 cells. Additionally, Wnt inhibitory factor 1 (WIF1) was demonstrated to be a direct target of miR‑552 in Hep3B and Huh‑7 cells. Additional experiments identified that miR‑552 promotes β‑catenin expression by increasing the phosphorylation of GSK3β at Ser9. In conclusion, the results suggested that miR‑552 may promote HCC progression by blocking WIF1‑mediated GSK3β dephosphorylation. miR‑552 may be a biomarker for predicting the outcomes of patients with HCC.
-derived novel-miR1 targets TLR2 to inhibit the immune response in rabbits.
Chen G, Pu G, Wang L, Li Y, Liu T, Li H Front Immunol. 2023; 14:1201455.
PMID: 37559722 PMC: 10408446. DOI: 10.3389/fimmu.2023.1201455.
Role of non-coding RNAs and exosomal non-coding RNAs in retinoblastoma progression.
Ahangar Davoodi N, Najafi S, Ghale-Noie Z, Piranviseh A, Mollazadeh S, Ahmadi Asouri S Front Cell Dev Biol. 2023; 10:1065837.
PMID: 36619866 PMC: 9816416. DOI: 10.3389/fcell.2022.1065837.
Li C, Chen S, Jiang Y Nan Fang Yi Ke Da Xue Xue Bao. 2022; 42(11):1587-1593.
PMID: 36504050 PMC: 9742782. DOI: 10.12122/j.issn.1673-4254.2022.11.01.
miR-340 Promotes Retinoblastoma Cell Proliferation, Migration and Invasion Through Targeting WIF1.
Li K, Han F, Wu Y, Wang X Onco Targets Ther. 2021; 14:3635-3648.
PMID: 34113129 PMC: 8187089. DOI: 10.2147/OTT.S302800.
MicroRNA-552 expression in colorectal cancer and its clinicopathological significance.
Im J, Nam S, Lee H J Pathol Transl Med. 2021; 55(2):125-131.
PMID: 33596633 PMC: 7987523. DOI: 10.4132/jptm.2021.01.17.